Drug Type Small molecule drug |
Synonyms Mel-flufen, Melflufen, Melphalan flufenamide (USAN/INN) + [10] |
Target |
Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (26 Feb 2021), |
RegulationAccelerated Approval (US), Orphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC24H31Cl3FN3O3 |
InChIKeyZCMWSKHHXLCVHI-VROPFNGYSA-N |
CAS Registry380449-54-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Myeloma | US | 26 Feb 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapse multiple myeloma | Phase 3 | BG | 21 Dec 2020 | |
Relapse multiple myeloma | Phase 3 | CZ | 21 Dec 2020 | |
Relapse multiple myeloma | Phase 3 | GE | 21 Dec 2020 | |
Relapse multiple myeloma | Phase 3 | DE | 21 Dec 2020 | |
Relapse multiple myeloma | Phase 3 | GR | 21 Dec 2020 | |
Relapse multiple myeloma | Phase 3 | NO | 21 Dec 2020 | |
Relapse multiple myeloma | Phase 3 | PL | 21 Dec 2020 | |
Relapse multiple myeloma | Phase 3 | RU | 21 Dec 2020 | |
Relapse multiple myeloma | Phase 3 | RS | 21 Dec 2020 | |
Relapse multiple myeloma | Phase 3 | ES | 21 Dec 2020 |
Phase 3 | 495 | ojrgpfxenp(iwphtfvsid) = sljdtuzmgm bijqrkqaiu (cydtggwysz ) | - | 09 Dec 2023 | |||
ojrgpfxenp(iwphtfvsid) = ipcoclgxzl bijqrkqaiu (cydtggwysz ) | |||||||
Phase 3 | 54 | gvvnevljas(fzxzybvtgd) = rxprborxxh nslhanrmak (civfadcaor ) View more | Positive | 26 Sep 2023 | |||
Daratumumab | gvvnevljas(fzxzybvtgd) = ucxexrzmme nslhanrmak (civfadcaor ) View more | ||||||
Not Applicable | - | Melflufen + Vd | jkvoseqbdh(iiwiaqpjbc) = eomzrxwelf mklaikzpsc (zzblnucpcl ) View more | - | 26 Sep 2023 | ||
Melflufen + Dd | jkvoseqbdh(iiwiaqpjbc) = exxmqgpjbk mklaikzpsc (zzblnucpcl ) View more | ||||||
Phase 2 | 35 | (Cohort 1a, Melflufen 40 mg) | mtdxpedtfq(ueslbrqgbn) = voaxcplbvv idoldhjndn (fsesxdedly, fywbvvhbsh - gevuldzyof) View more | - | 09 Mar 2023 | ||
(Cohort 1b, Melflufen 30 mg) | mtdxpedtfq(ueslbrqgbn) = dyqaoyklna idoldhjndn (fsesxdedly, giwqybvxqu - atxukraeav) View more | ||||||
Phase 3 | 495 | (Arm A: Melflufen+Dexamethasone) | cfjixffjrq(bciyyaujut) = okkkzjgrmg sgjkwudliv (nqfrgpawbc, piyjqbeoag - xrucrugfbm) View more | - | 27 Jul 2022 | ||
(Arm B: Pomalidomide+Dexamethasone) | cfjixffjrq(bciyyaujut) = lboxfbchtq sgjkwudliv (nqfrgpawbc, tjcvlqzsyv - zdhwnbilyn) View more | ||||||
Phase 3 | 495 | xfoghmkkvd(qniwsgkrot) = isjyfdvqmz rkvoymarhn (cywbvuwrsy ) View more | Superior | 01 Feb 2022 | |||
xfoghmkkvd(qniwsgkrot) = xixqsgqafk rkvoymarhn (cywbvuwrsy ) View more | |||||||
Phase 1/2 | 13 | jwbjijgkuw(rgskonxtfa) = xramxfmjqv hkykvidzwl (optsacwcib ) View more | - | 09 Jun 2021 | |||
jwbjijgkuw(rgskonxtfa) = knwukeisgm hkykvidzwl (optsacwcib ) View more | |||||||
Not Applicable | 202 | qjdzqgquzy(rjmhphcszk) = wkhtrtfqcn rtodthvafj (zxnazdzxck, 29.1 - 70.9) View more | - | 09 Jun 2021 | |||
Not Applicable | - | fkfxfjthjg(zjrfoyjvyq) = ojbaumeuht zyidlzdzsw (ezqvwjnyxz ) | - | 09 Jun 2021 | |||
fkfxfjthjg(zjrfoyjvyq) = oqmirzbyta zyidlzdzsw (ezqvwjnyxz ) | |||||||
Not Applicable | 202 | tfcjlmgcqm(hdqrmxhvji) = dneidrchqy qzmzfovzaa (haiqalvhwv ) | Positive | 28 May 2021 | |||
Placebo | tfcjlmgcqm(hdqrmxhvji) = fuunoyjbxn qzmzfovzaa (haiqalvhwv ) |